Table 1.
Baseline characteristics (n=78)
| Characteristic | Patients, n (%) |
|---|---|
| Histological subtype | |
| Ductal infiltration | 65 (83.3) |
| Lobular infiltration | 9 (11.5) |
| Others | 4 (5.1) |
| Hormone-receptor status | |
| ER-positive | 67 (85.9) |
| ER- and PgR-positive | 57 (73.1) |
| TNBC | 11 (14.1) |
| Grade (n=58) | |
| 1 | 7 (12.1) |
| 2 | 18 (31.0) |
| 3 | 33 (56.9) |
| Number of metastatic sites | |
| <3 | 33 (42.3) |
| ≥3 or liver metastases | 45 (57.7) |
| Previous treatment (adjuvant or metastatic setting) | |
| No anthracyclines or taxanes | 21 (26.9) |
| Anthracyclines | 18 (23.1) |
| Anthracyclines and taxanes | 39 (50.0) |
| Number of previous treatment lines for MBC | |
| 0 | 43 (55.1) |
| ≥1 | 35 (44.9) |
Abbreviations: ER, estrogen receptor; MBC, metastatic breast cancer; PgR, progesterone receptor; TNBC, triple-negative breast cancer.